chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Friend got hospitalized after Moderna; This spontaneous case was reported by a consumer and describes the occurrence of HOSPITALISATION (Friend got hospitalized after Moderna) in a  patient of an unknown age and gender who received mRNA-1273 (Spikevax) for COVID-19 prophylaxis.     No Medical History information was reported.    On an unknown date, the patient received dose of mRNA-1273 (Spikevax) (unknown route) 1 dosage form. On an unknown date, the patient experienced HOSPITALISATION (Friend got hospitalized after Moderna) (seriousness criterion hospitalization). At the time of the report, HOSPITALISATION (Friend got hospitalized after Moderna) outcome was unknown.        The action taken with mRNA-1273 (Spikevax) (Unknown) was unknown.       No concomitant medication was reported.  No treatment information was provided.  This case was identified as part of a retrospective clean-up activity where certain emails received in the Moderna mailbox were missed to be booked-in.  Company Comment: This spontaneous case concerns a patient, of unknown age and gender, with no medical history reported, who experienced the unexpected, serious event of hospitalisation. The event occurred unknown number of days after receiving an unspecified dose of the mRNA-1273 vaccine. Of note, the vaccination date and the event onset date were not provided, hence, the onset latency could not be assessed. It was reported that the patient got hospitalized after receiving the mRNA-1273 vaccine. No further clinical information (including symptoms, details about hospitalization, laboratory test/s and treatment) was available for medical review. The benefit-risk relationship of the mRNA-1273 vaccine is not affected by this report.; Sender's Comments: This spontaneous case concerns a patient, of unknown age and gender, with no medical history reported, who experienced the unexpected, serious event of hospitalisation. The event occurred unknown number of days after receiving an unspecified dose of the mRNA-1273 vaccine. Of note, the vaccination date and the event onset date were not provided, hence, the onset latency could not be assessed. It was reported that the patient got hospitalized after receiving the mRNA-1273 vaccine. No further clinical information (including symptoms, details about hospitalization, laboratory test/s and treatment) was available for medical review. The benefit-risk relationship of the mRNA-1273 vaccine is not affected by this report.
Developed pain to the left arm on 8/20/2020.   Is mildly swollen and tender on 9/17/2020 exam.  Is losing shoulder motion secondary to the pain.
Starting about 3 hours after the injection, right arm began feeling sore at the injection site.  Discomfort turned into pain in the late afternoon and evening, to a maximum pain level of about 4 by bedtime.  Pain level was down to about 2 or 3 by the next morning, and that continued throughout the next day.
measles like rash on left chest; low grade fever; chills; 2nd shot, swollen glands in neck; This is a spontaneous report from a contactable consumer (patient herself). A 78-year-old non-pregnant female patient received second dose of bnt162b2 (PFIZER-BIONTECH COVID-19 VACCINE, Formulation: Solution for injection, Lot number: El), via an unspecified route of administration in left arm on 11Feb2021 at 11:45 (at the age of 78-year-old) as a single dose for COVID-19 immunisation. The patient's medical history included COPD (chronic obstructive pulmonary disease). Concomitant medications were not reported. The patient previously received first dose of bnt162b2 (PFIZER-BIONTECH COVID-19 VACCINE, Formulation: Solution for injection) as a single dose for COVID-19 immunisation. The patient did not have any known allergies. The patient was not diagnosed with COVID-19 prior to the vaccination. The patient did not test for COVID-19 post vaccination. The patient did not receive any other vaccine in four weeks. It was reported that the patient experienced 2nd shot, swollen glands in neck on 11Feb2021 at 16:00, second day (12Feb2021), low grade fever and chills, third day (13Feb2021), measles like rash on left chest. All gone now. The patient underwent lab test and procedures which included body temperature: low grade fever on 12Feb2021. No treatment was received for the adverse events. The outcome of the events was recovered on an unspecified date in Feb2021.
Bad itching over entire body. No rash or redness noticed. Burning, pin pricking feeling. Nerves jumping.
patient received his 2nd dose of GARDASIL 9 at an interval of 13 months after the initial dose; no additional adverse events reported; This spontaneous report was received from a nurse practitioner and refers to a 12 years old male patient. No information regarding the patient's medical history, concurrent conditions, drug reactions or allergies and concomitant medications was provided.  On an unknown date, the patient was vaccinated with the first dose of hpv rl1 6 11 16 18 31 33 45 52 58 vlp vaccine (yeast) (GARDASIL 9) (formulation, dose, route of administration, anatomical location, lot # and expiration date were not reported) for prophylaxis.  On an unknown date, 13 months after the initial dose, the patient was vaccinated with the second dose of hpv rl1 6 11 16 18 31 33 45 52 58 vlp vaccine (yeast) (GARDASIL 9) (formulation, dose, route of administration, anatomical location, lot # and expiration date were not reported) for prophylaxis (inappropriate schedule of product administration).  There was no additional adverse event reported.
ACUTE DVT, UNSPECIFIED VEIN ACUTE DVT OF BILAT FEMORAL VEINS ACUTE PULMONARY EMBOLISM 3/14/2023  --  RECURRENCE OF HOSPITALIZATION WITH SAME SYMPTOMS
Pt went to ED for R-sided weakness and dizziness.  then subsequently had CVA.
I called the patient to find out if she wanted to get her second moderna vaccine (she was on our missed second dose report).  She told me that she had a reaction a couple of days after receiving the vaccine that resulted in a trip to the ER and ongoing medical care from her primary physician.  This reaction involved her skin becoming darker (a brown color) and some of her skin peeling off.  In addition her face is discolored and she said she had little to no blood flow in her lower arms and hands.  Her physician has placed her on steroids and is doing tests to try to figure out what is going on.  She does not have a definitive diagnosis and cannot be sure that this is due to the vaccine, but as it occurred within about 48 to 72 hours after receiving the vaccine (4/2/21) we are treating it as such according to CDC and FDA rules.
Big circular rash at site of injection appeared after 1 week, followed by weakness and dizziness every day since.
Incorrect diluent was used. Patient's parents notified and will come in to get this vaccine again.
Rash maculo-papular erythematous and certain area urticaria all over body incl. palms, soles, face, head-rash blanching on pressure, no fever, no vomiting, no diarrhea, no wheezing. Recheck 11/19/02, 70% rash resolved.
Received EL0142 on 01/04/21 at 1:30PM and EL9292 (writing difficult to read) at 1:15 PM. Went to the emergency room on 3/9/21 (43 days after 2nd shot) for symptoms of stroke. Was diagnosed with Bells Palsy.
Symptoms: one day after- slight pain at injection location, some body ache. Two days after: swollen lymph node, left underarm.
This case was reported by a pharmacist via call center representative and described the occurrence of injection site pain in a 68-year-old female patient who received SHINGRIX (batch number B9739 ?, expiry date unknown). On 25th May 2018, the patient received the 1st dose of SHINGRIX. On 26th May 2018, 1 days after receiving SHINGRIX, the patient experienced injection site pain, injection site warmth and injection site erythema. On an unknown date, the outcome of the injection site pain was recovering/resolving and the outcome of the injection site warmth and injection site erythema were not recovered/not resolved. The reporter considered the injection site pain, injection site warmth and injection site erythema to be almost certainly related to SHINGRIX. Additional details were provided as follows: The patient received SHINGRIX on left arm. The healthcare professional (HCP) had no expiry date for SHINGRIX. The redness was the size of the bottom of a small bottle of water as per the HCP (4 to 5 cm). The reported lot number (B9739) does not match any GSK lot number and was updated to B9739 ?.
pt recv vax & approx 2 wk p/vax exp arthritic type sx in the joints of hips, shoulders & knees;also devel a rash on thighs;30NOV95 sought medical attention;
Menstrual cycle 10 days early, lasted 7 days. Typical cycle every 29/31 days lasting 3-4 days
Eight days of flu symptoms. Injection site was red and warm for eight days. I'm no hypochondriac or weeny. Was truly shocked at this reaction.
muscle aches x 3 days, fatigue x 4 days, headaches x 4 days; did not seek medical treatment; 2/17/21 stated that the symptoms went away on 2/13/21 and have since been feeling fine.
Abrysvo vaccine is defective/could not insert the devices/little plastic pieces came out from the device; Due to unable to insertion for syringes I had to destroy 2 shots; This is a spontaneous report received from a contactable reporter(s) (Pharmacist) from product quality group, Program ID.  A patient (no qualifiers provided) received PF-06928316 (ABRYSVO), as dose number unknown, single (Batch/Lot number: unknown) for immunisation. The patient's relevant medical history and concomitant medications were not reported. The following information was reported: DEVICE DEFECTIVE (non-serious), described as "Abrysvo vaccine is defective/could not insert the devices/little plastic pieces came out from the device"; DEVICE USE ISSUE (non-serious), described as "Due to unable to insertion for syringes I had to destroy 2 shots".  Additional information: The pharmacist mentioned that the syringe of the Abrysvo vaccine is defective, and as a result, a patient was not able to get a dose of the product. She said that when pushed, the little plastic pieces came out and were no longer usable. She wants to get a replacement.  The pharmacist tried to prepare for injection for Abrysvo for patients and could not insert the devices and little plastic pieces came out from the device. Due to unable to insertion for syringes, the pharmacist had to destroy 2 shots.     The information on the batch/lot number for PF-06928316 has been requested and will be submitted if and when received.
Fever, oral discomfort, anorexia, chills, rhinorrea for 10 days.
started getting rash on left torso under arm on 3/3 then noticed vesicles on 3/6 in distribution of shingles
This spontaneous report as received from a nurse, refers to unspecified patients of unknown demography. No concurrent condition, medical history or allergy/drug reactions were reported. On an unspecified date, since 02-JUN-2015, unspecified number of patients were vaccinated with improperly stored VAQTA injection (lot # K019560, expiration date: 02-JUN-2017) (strength, dose and route unspecified). No concomitant medications were reported. No adverse effect had been observed or reported. The outcome of the event was unknown. There were no product quality complaints (PQC) involved. No additional information was provided. This is one of several reports received from the same reporter. Follow up information has been received on 13-JUL-2015, that all telephone attempts to obtain follow-up information have been unsuccessful. Follow up information was received on 20-JUN-2015 with additional information on 21-JUN-2015. The patient was approximately 12 months old. The patient demographics were updated. On 19-JUN-15 the patient was vaccinated with improperly stored VAQTA (lot # K019560, expiration date: 02-JUN-2017) (strength, dose and route unspecified). Additional information has been requested. Patient, suspect therapy and narrative were updated.
This case was reported by a pharmacist via call center representative and described the occurrence of injection site pain in a elderly female patient who received SHINGRIX (batch number XN24S, expiry date 29th November 2020) for prophylaxis. In July 2018, the patient received the 1st dose of SHINGRIX. In July 2018, immediately after receiving SHINGRIX, the patient experienced injection site pain. On an unknown date, the outcome of the injection site pain was not recovered/not resolved.  It was unknown if the reporter considered the injection site pain to be related to SHINGRIX. Additional details were provided as follows: The age at the vaccination was not reported. The patient had an immediate sharp pain at the injection site after receiving a dose of SHINGRIX. The pain was still noted when the patient reaches for something or stretches her arm. The reporter consented to follow up.
This is continuation of worsening symptoms since last report. On August 18,2021 got sick went to clinic high fever, terrible back pain and urinary symptoms. I was so exhausted was in bed for 24 to 48 hours. After Dose 3 blood counts bone marrow failure diagnosed with aplastic anemia on January 20, 2022. I started treatment for aplastic anemia on Monday January 24, 2022.
4:30pm pt noticed tingling & hot flash of face and neck- stiffness of jaw took 50mg of Benadryl. 530-6pm pt noticed the addition of numbness and tingling arms. Pt slept. Pt woke at 11:30pm and noticed that tingling was gone. Pt woke this morning and reports to feeling fine.
On 10/30/21 started developing itching in my face and throat. By the next day the itching had extended down my whole body. By Monday the itching was excruciating and a full body rash developed. Went to the Er but they could not identify cause so they gave me oral prednisone, doxycycline, diphenhydramine and sent me home with prescriptions for the doxy, and 50mg prednisone to take daily.  By Tuesday I began swelling in head neck face both arms trunk and legs.  Went back to ER where I began experiencing extreme joint pain. They determined it was either an allergic reaction or auto immune. They gave me IV methyprednisolone and ketorolac. They referred me to an immunologist who I saw today (Thursday). He felt it was a delayed allergic reaction to the vaccine. Currently the full body swelling and rash have not subsided yet.
This case was reported by a consumer via call center representative and described the occurrence of whooping cough in a 60-year-old male patient who received dTpa vaccine for prophylaxis. On an unknown date, the patient received dTpa vaccine at an unknown dose. On 1st January 2015, unknown after receiving dTpa vaccine, the patient experienced whooping cough (serious criteria hospitalization and GSK medically significant), cough (serious criteria hospitalization) and atrial fibrillation (serious criteria hospitalization and GSK medically significant). On an unknown date, the patient experienced loss of energy (serious criteria hospitalization), heart rate increased (serious criteria hospitalization) and activities of daily living impaired. On an unknown date, the outcome of the whooping cough, cough, atrial fibrillation, loss of energy, heart rate increased and activities of daily living impaired were unknown. It was unknown if the reporter considered the whooping cough, cough, atrial fibrillation, loss of energy, heart rate increased and activities of daily living impaired to be related to dTpa vaccine. Additional details were provided as follows: The age at the vaccination was not reported. In 2013, the patient received whooping cough booster probably. In December 2014, the patient was on cruise for a vacation. On 1st January 2015, the patient was home from the cruise and started coughing violently. The patient saw his health care professional as soon as he could after New Year's and was sent to the hospital for atrial fibrillation. The patient was hospitalized several times until getting an ablation on 1st April 2015. The patient coughed the entire time, but his providers were all concerned with his atrial fibrillation and did not think anything of it. After the ablation, his health care professional finally referred him to a tropical and infectious diseases specialist and the patient was diagnosed with whooping cough. After the ablation the coughing improved some, but he continued to had regular coughing episodes. The patient was hospitalized a couple more times because of a fast heart rate until he had a second ablation on 1st April 2016. Prior to the 2nd ablation the patient did not have any energy and could not do things like walk the dog. After the 2nd ablation, as soon as the patient woke up he knew it had worked because he could not feel his heart beating for the first time since 2014. The two ablations both occurred on 1st April one year apart (2015 and 2016). The coughing continued until spring of 2017. The reporter thought the whooping cough caused him to go into atrial fibrillation. The patient had recovered from whooping cough and atrial fibrillation and was physically active again. Emergency room visit was required. The reporter consented to follow up. Lab Comments: On an unknown date, the heart rate was measured.
positive COVID-19 test with symptoms; positive COVID-19 test with symptoms; This is a spontaneous report from a non-contactable consumer (patient herself). An 18-year-old female patient received BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, Solution for injection), intramuscularly, administered in the left arm on 24Mar2021 at 11:00 (Batch/Lot Number: EP6955) as the 1st dose, single and intramuscularly, administered in the left arm on 14Apr2021 at 09:00 (Batch/Lot Number: EP6955) as the 2nd dose, single for COVID-19 immunization. The facility where the most recent COVID-19 vaccine was administered was at the workplace clinic. Relevant medical history included depression and known allergies to eggs when younger; both from an unknown date and unknown if ongoing. Concomitant medications included fluoxetine hydrochloride (PROZAC) and lamotrigine (LAMICTAL); both taken for an unspecified indication, start and stop date were not reported. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. Prior to vaccination, the patient was not diagnosed with COVID-19. The patient was not pregnant at the time of vaccination. On 12May2021 at 10:00, the patient experienced positive COVID-19 test with symptoms of severe throat lesions. The adverse event (AE) resulted in a doctor or other healthcare professional office/clinic visit. The patient underwent lab tests and procedures, which included Covid test via Nasal Swab, which was negative on 02May2021 and positive on 12May2021. Therapeutic measures were taken as a result of positive COVID-19 test with symptoms, which included medication for severe throat lesions. The patient was recovering from the event.  No follow-up attempts are possible. No further information is expected.
S/s of fever 103, headache, chills, muscle pain, Supraclavicular and axillary lymph node enlargement and pain
4 x 3 1/2" reddened area, warm, hard to touch. AMOXIL - PO & clavulanate 600 - 42.9 mg 1 tsp PO BID x 10 days.
That night was sitting in the chair, my heart was racing and pounding, I didn't do anything; thought it would go away. It continued for about a week I called my doctor, was informed to go to ER. I went to the ER; blood pressure was going down and up. Was given Aspirin. I was monitored. About 2 days later I experienced 24 hours of diarrhea; started feeling better.
Patient that received the Pfizer, and it was discovered after the fact that the patient was only 10 years old.  We checked in with patient multiple times while she was here to verify that she was feeling okay and explained that the vaccine is not recommended as of now for patients under 12 years old.
awoke next morning w/pain supraclavicular area, next day pain in axilla & swelling/heat @ site of inject afebrile; swollen glands; erythema, warmth, lt deltoid;
Information has been received from a mother concerning her daughter who on approximately 10/18/2002 was vaccinated with varicella vaccine. Subsequently, the pt developed chicken pox. Additional info has been requested.
Sleep disturbed; Joint pain; This spontaneous case was reported by a consumer and describes the occurrence of SLEEP DISORDER (Sleep disturbed) and ARTHRALGIA (Joint pain) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.   On an unknown date, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On an unknown date, the patient experienced SLEEP DISORDER (Sleep disturbed) and ARTHRALGIA (Joint pain). The patient was treated with ADALIMUMAB (HUMIRA) (subcutaneous) for Psoriatic arthritis, at an unspecified dose and frequency. At the time of the report, SLEEP DISORDER (Sleep disturbed) outcome was unknown and ARTHRALGIA (Joint pain) had resolved.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.    No concomitant medications were reported.   Reporter did not allow further contact
fever; nausea; chills; headache; achy; This is a spontaneous report from a contactable consumer (Certified Nursing Assistant) reported for a male patient. A male patient of unspecified age received first dose of bnt162b2 (Pfizer COVID-19 Vaccine, solution for injection, Lot number: unknown), via an unspecified route on an unknown date as a single dose for COVID-19 immunization. Medical history included COVID-19. The patient concomitant medications were not reported. On an unknown date, patient had a reaction after his first Covid-19 vaccine. Details of the event was not known. Patient had a fever and reporter was surprised at that because he had Covid prior to the vaccine as well. He had nausea and fever and similar symptoms (achey, chills, headache) she (reporter) was experiencing. The patient had not undergone relevant medical tests. The clinical outcome of the events was unknown.  No follow-up attempts are needed. No further information is expected.
06:30pm I started to feel achy (flu-like achy); throat was sore and tight; nauseated. I got an increasingly bad headache. I had taken a couple of regular strength Tylenol - a little before 06:30 pm mostly to prevent soreness in my arm. Around 7:15 or 7:30, I felt this wave of fatigue wash over me and I was chilled and I crashed on the bed - blankets around me with hot water bottle. Fatigue and chills lifted around 11 pm; headache, aches and sore throat remained. Around midnight, in addition, my chest started to tighten up again although not as bad as the first time; tooth pain and jaw pain and tingling down both of my arms. It was worse on the right. About 1:30 am on the 9th, the tingling started moving up over my scalp and over my head. My heart was pounding again and it was like having an anxiety attack without the anxiety. I had pretty much all the same symptoms as I had the first vaccine but it wasn't as bad - it was a milder version of them. I couldn't fall asleep until 07:30 am and slept until 2:30 pm and the symptoms persisted. Later that day, on the ninth, my lungs were off gassing chemicals it seemed and I felt it is a mist was going off in my brain. Both of these things, I have experienced before and they seem to be kind of random and they don't really have a cause for them. Same thing for the symptoms continuing - note on April 23rd - diminishing slowly. Heart pounding continued - Pulsometer showed it around 70 or so but it felt it was really pounding. I had the nausea, headache, sore throat, achiness, blah feeling - flu-like symptoms again - these would pop up randomly for a few days and then go away. They were gone when I saw my doctor on the 3rd of May but they had not been gone long. (So between the 23rd of April and May 3rd they went away.) This does seem to have made my ME a little worse - I seem to be a little fatigued then I was before - everything else has gone.